Drug Discovery World

MARCH 4, 2024

In an early phase clinical trial, a combination of antibody-based medications targeting the immune system generated promising safety data and anti-tumour activity in individuals with advanced cancer. Both medications tested in the trial support immune responses against tumour cells.

Antibody 115

Antibody Immune Response Trials Clinical Trials 115

Pharmaceutical Technology

DECEMBER 6, 2022

The three leading Alzheimer’s disease (AD) drugs currently in development are all monoclonal antibodies—donanemab by Eli Lilly , lecanemab by Eisai and Biogen , and gantenerumab by Roche. Monoclonal antibodies make up half of these, with an 11% share of all AD approvals.

Antibody 147

Antibody Marketing Drugs Trials 147

Drug Discovery World

MARCH 12, 2024

Here, experts weigh in on the future of monoclonal antibodies (mAbs). Amanda Halford, President Bioprocess, Cytiva “In 2024, the emphasis will remain on novel mAbs, specifically antibody drug conjugates. Innovations include next-generation antibodies with improved efficacy and reduced side effects.

Antibody 81

Antibody FDA Approval Drugs Development 81

Drug Discovery World

OCTOBER 12, 2023

The US Food and Drug Administration (FDA) has granted clearance to Transcenta to proceed with its TranStar 301 global Phase III pivotal trial of Osemitamab (TST001) for gastric cancer. The trial will investigate the drug in combination with Nivolumab and chemotherapy as a first-line treatment in patients with HER2-negative, CLDN18.2

Antibody 52

Antibody Trials Drugs Medicine 52

Medical Xpress

APRIL 19, 2023

A treatment combining two antibodies against the coronavirus SARS-CoV-2 strongly protected high-risk people with early COVID-19 symptoms from hospitalization and death in an international Phase 2/3 clinical trial conducted in the first half of 2021 and co-led by researchers at Weill Cornell Medicine and NewYork-Presbyterian.

Antibody 89

Antibody Trials Clinical Trials Clinical Trials 89

Outsourcing Pharma

FEBRUARY 23, 2021

The pharma firm is partnering with the decentralized research organization on a Phase III trial testing a long-acting antibody combination treatment.

Antibody 78

Antibody Trials Research 78

Drug Discovery World

OCTOBER 11, 2023

Collaborators Boehringer Ingelheim and CDR-Life have commenced a Phase I evaluation of BI 771716, their antibody fragment-based treatment developed to preserve the vision of people with geographic atrophy (GA). The company’s first therapeutic candidate, CDR404, targets MAGE-A4 and is expected to enter the clinic in 2024.

Clinical Trials 52

Clinical Trials Clinical Trials Antibody Trials 52

Drug Discovery World

JULY 6, 2023

The first patient has been dosed in the clinical Phase I evaluation of the Sema3A monoclonal antibody, part of the Evotec-Bayer multi-target research collaboration in kidney diseases. The post First patient dosed in trial of antibody for kidney disease appeared first on Drug Discovery World (DDW).

Antibody 52

Antibody Trials Genetics Protein 52

STAT News

DECEMBER 10, 2022

NEW ORLEANS — Researchers had hoped in recent years that a protein called GPRC5D might offer a new way to get the immune system to hunt down and destroy multiple myeloma cells. Now, the results of a Phase 2 study on a bispecific antibody targeting this protein offers confirmation.

Antibody 132

Antibody Protein Trials Research 132

pharmaphorum

SEPTEMBER 16, 2020

Regeneron’s COVID-19 antibody cocktail has been added to the UK’s RECOVERY trial, one of the largest of its kind in the world that is testing several potential coronavirus therapies at the same time. REGN-COV2 is a combination of two monoclonal antibodies, designed to block infections of SARS-CoV-2, the virus that causes COVID-19.

Antibody 97

Antibody Trials Manufacturing Protein 97

Drug Discovery World

JUNE 1, 2023

Antibody-drug conjugates (ADCs) are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker 1. To overcome this challenge, Synaffix has developed an innovative technology platform that can rapidly and efficiently convert any antibody into an ADC.

Antibody 98

Antibody Marketing Drugs Licensing 98

Drug Discovery World

JULY 26, 2023

A Cancer Research UK-funded clinical trial has shown, for the first time, that a new class of antibody could benefit cancer patients whose existing treatments have stopped working. The drug, MOv18 IgE, was developed by researchers at King’s College London.

Antibody 52

Antibody Drugs Clinical Trials Clinical Trials 52

Drug Discovery World

NOVEMBER 15, 2022

DynamiCure has dosed the first patients in its Phase I clinical trial evaluating the first of the company’s two anti-CD93 monoclonal antibody candidates, DCBY02, in adults with a wide range of advanced cancers. . The post Phase I trial of lead antibody candidate launched appeared first on Drug Discovery World (DDW).

Antibody 52

Antibody Trials Clinical Trials Clinical Trials 52

XTalks

DECEMBER 28, 2023

BillionToOne, a company specializing in molecular diagnostics, has partnered with Janssen Research & Development, LLC, a Johnson & Johnson division, to conduct the AZALEA Phase III clinical trial globally. The trial is set to occur across the US, the European Union (EU) and selected global locations.

Trials 97

Trials Clinical Trials Clinical Trials Antibody 97

BioTech 365

DECEMBER 20, 2021

Global TROP2 Antibody Market & Clinical Trials Insight Research Report 2021-2026 – ResearchAndMarkets.com Global TROP2 Antibody Market & Clinical Trials Insight Research Report 2021-2026 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Global TROP2 Antibody Market & Clinical Trials Insight 2026” (..)

Clinical Trials 40

Clinical Trials Clinical Trials Antibody Marketing 40

STAT News

AUGUST 3, 2022

An experimental antibody treatment prevented malaria in the majority of participants in a small but important new study , providing a measure of hope in the effort to lower the burden of the disease worldwide. Read the rest…

Antibody 105

Antibody Clinical Trials Clinical Trials Trials 105

XTalks

MAY 2, 2022

Lecanemab, the product of Phase IIb clinical research completed by BioArctic and collaborator Eisai, is one therapy making strides this year for Alzheimer’s disease. This year, the monoclonal antibody lecanemab is approaching final stages of investigation as a treatment for targeting the A? Next Stages in Clinical Research.

Clinical Trials 98

Clinical Trials Clinical Trials Antibody Trials 98

Pharmaceutical Technology

NOVEMBER 29, 2022

Researchers at City of Hope in the US have developed a new potential therapy to treat glioblastoma multiforme (GBM), a kind of brain cancer. This chemokine is connected to the epidermal growth factor receptor (EGFR) antibody causing attachment to tumour cells. These viruses are engineered genetically for killing cancer.

Development 130

Development Research Antibody Engineer 130

Drug Discovery World

NOVEMBER 2, 2022

One dose of an antibody drug safely protected healthy, non-pregnant adults from malaria infection during an intense six-month malaria season in Mali, Africa. . The antibody was up to 88.2% The Phase II NIAID-USTTB trial evaluated a one-time, intravenous infusion of a monoclonal antibody called CIS43LS. .

Antibody 52

Antibody Allergies Trials Medicine 52

Drug Discovery World

DECEMBER 8, 2023

ONK Therapeutics and NAYA Biosciences have agreed to develop a combination therapy of ONK’s optimally-engineered natural killer (NK) cell therapies and NAYA’s FLEX-NK bispecific antibodies. ONK and NAYA plan to assess several combination therapies in preclinical cancer models in 2024 prior to subsequently exploring initiating clinical trials.

Antibody 52

Antibody Gene Editing Clinical Trials Clinical Trials 52

Drug Discovery World

FEBRUARY 28, 2024

Lu Rahman selects some of the year’s interesting and noteworthy advances in cancer research drug discovery and development. In the UK, according to Cancer Research UK, around 167,000 people die from cancer in the UK each year. Research into new drugs and therapeutics is on-going and is helping drive mortality rates down.

Development 64

Development Research Drugs Antibody 64

Drug Discovery World

SEPTEMBER 7, 2023

In the Phase III innovaTV 301 trial in recurrent or metastatic cervical cancer patients with disease progression on or after front-line therapy, Tivdak (tisotumab vedotin-tftv), compared with chemotherapy alone, met its primary endpoint of overall survival (OS).

Antibody 52

Antibody Drugs Trials Research 52

XTalks

JANUARY 17, 2024

Given this hotbed of activity, innovation in the space to drive faster decisions and more efficient trials is intense. They discussed the top new trends in oncology trial design that sponsors are either incorporating into clinical trials or need to start planning to include.

Clinical Trials 124

Clinical Trials Clinical Trials Trials Gene Therapy 124

Drug Discovery World

MAY 31, 2023

Immuno-oncology company Aulos Bioscience has revealed interim results from an ongoing Phase I/II trial of monoclonal antibody AU-007 in solid tumours. AU-007 is a human IgG1 monoclonal antibody designed using artificial intelligence to harness the power of interleukin-2 (IL-2) to eradicate solid tumours. “In

Antibody 52

Antibody Trials Clinical Trials Clinical Trials 52

Roots Analysis

AUGUST 9, 2023

Novel antibody therapies are chimeric proteins having antibodies attached lethal effector molecules. Multiple novel antibody formats have been engineered to enhance therapeutic efficacy. Around 50% of the articles focused on novel antibody therapies were published post-2020.

Antibody 52

Antibody Marketing Development Engineer 52

Scienmag

AUGUST 10, 2020

– The COVID-19 Prevention Network (CoVPN) today announced two Phase 3 trials to determine whether monoclonal antibodies (mAbs) can prevent SARS-CoV-2, the virus that causes COVID-19. Credit: CoVPN DURHAM, N.C.

Antibody 84

Antibody Research Trials Clinical Trials 84

Drug Discovery World

OCTOBER 25, 2023

Iksuda Therapeutics has dosed the first patient in a Phase I trial of antibody drug conjugate (ADC) IKS014 in patients with advanced solid tumours that express HER2. This follows positive data from Phase I clinical trials through Fosun Pharma, which is now progressing FS-1502 (IKS014) through Phase II and Phase III trials in China.

Antibody 52

Antibody Drugs Trials Clinical Trials 52

BioTech 365

JANUARY 27, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Care Access Research teams up with AstraZeneca for COVID-19 antibody virtual trial work.Care Access Research teams up with AstraZeneca for COVID-19 antibody virtual trial work badams Wed, … Continue reading →

Antibody 40

Antibody Trials Research 40

pharmaphorum

OCTOBER 25, 2021

Expectations for Novartis’ canakinumab as a therapy for cancer have taken another dive, after a second phase 3 trial in non-small cell lung cancer (NSCLC) failed to meet its primary objectives. The post Strike two for Novartis’ lung cancer antibody canakinumab appeared first on.

Antibody 116

Antibody Trials Branding Protein 116

pharmaphorum

SEPTEMBER 30, 2020

Regeneron’s antibody cocktail seems to reduce levels of coronavirus and improve symptoms in patients, according to early test results. This first data comes from a descriptive analysis from the seamless phase 1/2/3 trial that Regeneron hopes will hurry the medicine dubbed REGN-COV2 to market. There were no deaths in the trial.

Antibody 135

Antibody Immune Response Trials Protein 135

Drug Discovery World

OCTOBER 10, 2023

Aulos Bioscience has revealed new safety and efficacy data from the Phase I dose escalation portion of its Phase I/II clinical trial of AU-007 in patients with unresectable locally advanced or metastatic solid tumour cancers. The post Data supports IgG1 monoclonal antibody for solid tumours appeared first on Drug Discovery World (DDW).

Antibody 52

Antibody Trials Clinical Trials Clinical Trials 52

pharmaphorum

FEBRUARY 9, 2021

An international trial led by US experts is to begin testing AstraZeneca’s long-acting antibody combination therapy to treat COVID-19. The combination known as AZD7442 is to be added to the phase 3 adaptive trial called ACTIV-3, where investigators add new sub-studies of investigational new agents.

Antibody 52

Antibody Trials Allergies Engineer 52

Drug Discovery World

APRIL 11, 2024

By understanding what triggers the adaptive immune response in “elite responders” we have identified new targets and therapeutic antibodies. Anyone involved in developing medicines from an early stage, knows that the road from idea to patients is full of unexpected trials and tribulations.

Research 59

Research Immune Response Antibody Medicine 59

pharmaphorum

JANUARY 21, 2022

A third dose of vaccine has been shown to effectively neutralise the Omicron variant of covid-19, according to researchers. Research led by UCLH, UCL and the Francis Crick Institute found that the booster dose successfully stimulates antibody levels that neutralise Omicron. Overall, antibody levels were nearly 2.5

Antibody 100

Antibody Vaccination Vaccine Genotype 100

Pharmaceutical Technology

FEBRUARY 3, 2023

Only a few weeks into the new year, the prospect of getting a successful advanced HIV vaccine shrank after the discontinuation of yet another late-stage trial. This marks the second time one of Janssen’s HIV vaccines failed after another showed disappointing results in the Phase IIb Imbokodo trial in August 2021.

Vaccination 293

Vaccination Vaccine Antibody Trials 293

BioPharma Reporter

OCTOBER 27, 2020

The clinical research solutions firm is joining forces with pharma giant Eli Lilly to manage mobile research of the monoclonal antibody LY-CoV555.

Research 98

Research Antibody Clinical Research Trials 98

Drug Discovery World

APRIL 3, 2024

In the last few years, immunotherapies like immune checkpoint inhibitors, vaccines and cell and gene therapies have revolutionised the treatment of cancer, and targeted drugs like monoclonal antibodies (mAbs), poly-ADP ribose polymerase (PARP) inhibitors and targeted protein degraders are also playing an important role.

Research 52

Research Drugs Gene Therapy Genetics 52